Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 3/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623173 | 1.00 | USP30 (0.48) | USP30KDM4EFPR2RORCCNR1 | |
| SCHEMBL23612159 | 0.93 | KDM4E (0.44) | USP30KDM4EFPR2RORCCNR1 | |
| SCHEMBL23291499 | 0.88 | STS (0.50) | USP30KDM4EFPR2CNR1MEN1 | |
| SCHEMBL15168346 | 0.86 | USP30 (0.49) | USP30KDM4EFPR2RORCMEN1 | |
| SCHEMBL19202529 | 0.86 | ESR2 (0.51) | USP30KDM4ECNR1MEN1KMT2A | |
| SCHEMBL30912590 | 0.85 | NR1H2 (0.49) | USP30KDM4ECNR1MEN1KMT2A | |
| SCHEMBL22059962 | 0.85 | KDM4E (0.46) | USP30KDM4ECNR1MEN1KMT2A | |
| SCHEMBL30700671 | 0.85 | KDM4E (0.46) | USP30KDM4ECNR1MEN1KMT2A | |
| SCHEMBL38658196 | 0.84 | GPR119 (0.46) | USP30KDM4ECNR1MEN1KMT2A | |
| SCHEMBL30271952 | 0.84 | PDE4B (0.47) | USP30KDM4EFPR2RORCSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | USP30 156/4885KDM4E 2393/4885FPR2 4753/4885 |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | USP30 2353/4885KDM4E 3761/4885FPR2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.